Yahoo Finance " FIRST FDA APPROVED MIGRAINE PATCH APPROVED" LINKED
First FDA-Approved Migraine Patch Conference Call Scheduled January 18 at 8:30 a.m. EST
MarketwirePress Release: NuPathe Inc. – 2 minutes 9 seconds ago
CONSHOHOCKEN, PA--(Marketwire - Jan 17, 2013) - NuPathe Inc. ( NASDAQ : PATH ) today announced that the U.S. Food and Drug Administration (FDA) has approved Zecuity™ (sumatriptan iontophoretic transdermal system) for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Zecuity provides relief of both migraine headache pain and migraine-related nausea (MRN).
"The approval of Zecuity represents a major milestone for NuPathe and migraine sufferers," said Armando Anido, CEO of NuPathe. "As the first and only FDA-approved migraine patch, we believe Zecuity will be a game-changing treatment option for millions of migraine patients, especially those with migraine-related nausea. We thank the patients and physicians who participated in our clinical trials as well as our employees for their support throughout the development of Zecuity. We now intensify our focus to securing commercial partners and preparing for the launch of Zecuity